Page 379 - Read Online

Page 14 of 19 Marasco et al. Hepatoma Res 2020;6:33 I http://dx.doi.org/10.20517/2394-5079.2020.01

prognosis and recurrence after surgical resection. Hepatol Int 2019;13:715-25.
48. Liao M, Chen P, Liao Y, Li J, Yao W, et al. Preoperative high-sensitivity C-reactive protein to lymphocyte ratio index plays a vital role in
the prognosis of hepatocellular carcinoma after surgical resection. Onco Targets Ther 2018;11:5591-600.
49. Hung HC, Lee JC, Cheng CH, Wu TH, Wang YC, et al. Impact of neutrophil to lymphocyte ratio on survival for hepatocellular carcinoma
after curative resection. J Hepatobiliary Pancreat Sci 2017;24:559-69.
50. Zheng J, Cai J, Li H, Zeng K, He L, et al. Neutrophil to lymphocyte ratio and platelet to lymphocyte ratio as prognostic predictors for
hepatocellular carcinoma patients with various treatments: a meta-analysis and systematic review. Cell Physiol Biochem 2017;44:967-81.
51. Itoh S, Yugawa K, Shimokawa M, Yoshiya S, Mano Y, et al. Prognostic significance of inflammatory biomarkers in hepatocellular
carcinoma following hepatic resection. BJS Open 2019;3:500-8.
52. Liao M, Qin W, Liao Y, Yao R, Yu J, et al. Prognostic value of gamma-glutamyl transpeptidase to lymphocyte count ratio in patients with
single tumor size ≤ 5 cm hepatocellular carcinoma after radical resection. Front Oncol 2019;9:347.
53. Shi S, Chen Q, Ye L, Yin D, Li X, et al. Prognostic value of systemic inflammation score in patients with hepatocellular carcinoma after
hepatectomy. Oncotarget 2017;8:79366-75.
54. Wu J, Ma XL, Tian L, Zhang CY, Wang BL, et al. Serum IgG4: IgG ratio predicts recurrence of patients with hepatocellular carcinoma
after curative resection. J Cancer 2017;8:1338-46.
55. Chan AWH, Zhong J, Berhane S, Toyoda H, Cucchetti A, et al. Development of pre and post-operative models to predict early recurrence
of hepatocellular carcinoma after surgical resection. J Hepatol 2018;69:1284-93.
56. Tokumitsu Y, Sakamoto K, Tokuhisa Y, Matsui H, Matsukuma S, et al. A new prognostic model for hepatocellular carcinoma recurrence
after curative hepatectomy. Oncol Lett 2018;15:4411-22.
57. Cabibbo G, Petta S, Calvaruso V, Cacciola I, Cannavò MR, et al.; Rete Sicilia Selezione Terapia - HCV (RESIST-HCV). Is early
recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective
multicentre study. Aliment Pharmacol Ther 2017;46:688-95.
58. Petta S, Cabibbo G, Barbara M, Attardo S, Bucci L, et al. Hepatocellular carcinoma recurrence in patients with curative resection or
ablation: impact of HCV eradication does not depend on the use of interferon. Aliment Pharmacol Ther 2017;45:160-8.
59. Singal AG, Rich NE, Mehta N, Branch A, Pillai A, et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular
carcinoma in a multicenter North American cohort study. Gastroenterology 2019;156:1683-92.e1.
60. Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related
cirrhosis treated with direct-acting antivirals. J Hepatol 2016;65:727-33.
61. Wu JC, Huang YH, Chau GY, Su CW, Lai CR, et al. Risk factors for early and late recurrence in hepatitis B-related hepatocellular
carcinoma. J Hepatol 2009;51:890-7.
62. Donato F, Tagger A, Gelatti U, Parrinello G, Boffetta P, et al. Alcohol and hepatocellular carcinoma: the effect of lifetime intake and
hepatitis virus infections in men and women. Am J Epidemiol 2002;155:323-31.
63. Kudo A, Tanaka S, Ban D, Matsumura S, Irie T, et al. Alcohol consumption and recurrence of non-B or non-C hepatocellular carcinoma
after hepatectomy: a propensity score analysis. J Gastroenterol 2014;49:1352-61.
64. Bai F, Zhou H, Ma M, Guan C, Lyu J, et al. A novel RNA sequencing-based miRNA signature predicts with recurrence and outcome of
hepatocellular carcinoma. Mol Oncol 2018;12:1125-37.
65. Vasuri F, Fittipaldi S, De Pace V, Gramantieri L, Bertuzzo V, et al. Tissue miRNA 483-3p expression predicts tumor recurrence after
surgical resection in histologically advanced hepatocellular carcinomas. Oncotarget 2018;9:17895-905.
66. Oh J, Lee JM, Park J, Joo I, Yoon JH, et al. Hepatocellular carcinoma: Texture analysis of preoperative computed tomography images can
provide markers of tumor grade and disease-free survival. Korean J Radiol 2019;20:569-79.
67. Lee S, Kim SH, Hwang JA, Lee JE, Ha SY. Pre-operative ADC predicts early recurrence of HCC after curative resection. Eur Radiol
2019;29:1003-12.
68. Rimola J, Forner A, Sapena V, Llarch N, Darnell A, et al. Performance of gadoxetic acid MRI and diffusion-weighted imaging for the
diagnosis of early recurrence of hepatocellular carcinoma. Eur Radiol 2020;30:186-94.
69. Ahn SJ, Kim JH, Park SJ, Kim ST, Han JK. Hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MR imaging can predict
early recurrence after curative resection using image features and texture analysis. Abdom Radiol 2019;44:539-48.
70. Lee S, Kim SH, Lee JE, Sinn DH, Park CK. Preoperative gadoxetic acid–enhanced MRI for predicting microvascular invasion in patients
with single hepatocellular carcinoma. J Hepatol 2017;67:526-34.
71. Shan Q, Hu H, Feng S, Peng Z, Chen S, et al. CT-based peritumoral radiomics signatures to predict early recurrence in hepatocellular
carcinoma after curative tumor resection or ablation. Cancer Imaging 2019;19:11.
72. Lambin P, Rios-Velazquez E, Leijenaar R, Carvalho S, Van Stiphout RGPM, et al. Radiomics: extracting more information from medical
images using advanced feature analysis. Eur J Cancer 2012;48:441-6.
73. Kim S, Shin J, Kim DY, Choi GH, Kim MJ, et al. Radiomics on gadoxetic acid-enhanced magnetic resonance imaging for prediction of
postoperative early and late recurrence of single hepatocellular carcinoma. Clin Cancer Res 2019;25:3847-55.
74. Zheng J, Chakraborty J, Chapman WC, Gerst S, Gonen M, et al. Preoperative prediction of microvascular invasion in hepatocellular
carcinoma using quantitative image analysis. J Am Coll Surg 2017;225:778-88.e1.
75. Wang J, Shan Q, Liu Y, Yang H, Kuang S, et al. 3D MR elastography of hepatocellular carcinomas as a potential biomarker for predicting
tumor recurrence. J Magn Reson Imaging 2019;49:719-30.
76. Fujiwara N, Nakagawa H, Kudo Y, Tateishi R, Taguri M, et al. Sarcopenia, intramuscular fat deposition, and visceral adiposity
independently predict the outcomes of hepatocellular carcinoma. J Hepatol 2015;63:131-40.